In January 2026 Serina received FDA clearance of its IND application for SER-252, its lead POZ Platform™ candidate targeting advanced Parkinson’s disease. The company enrolled and dosed the first patient in a Phase 1b registrational trial in February 2026, marking its transition to clinical-stage development.

On March 17, 2026 Serina entered into definitive agreements to privately place common stock and pre-funded warrants to raise at least $15 million initially, with additional closings planned to reach up to $30 million. The structure includes 50% warrant coverage for potential proceeds up to $33.3 million, and as of March 23, 2026, $16.0 million in gross proceeds have been received.

Under a Capital on Demand™ Sales Agreement established in April 2025, Serina may offer up to $13.3 million of common stock. In 2026 the company sold 3.0 million shares at an average $3.36 per share for $10.0 million, bringing total ATM proceeds to $12.9 million from 3.5 million shares.

For the year ended December 31, 2025, Serina’s operating expenses rose to $24.2 million from $17.1 million in 2024, driven by higher clinical activity and headcount. Research and development costs increased to $13.2 million and general and administrative expenses to $11.0 million, while other income fell to $4.8 million.